Alberto Aguilera,7.
28015 Madrid. Spain.
Phone +34 912.670.900
Fax +34 912.670.901
info@tcdpharma.com
www.tcdpharma.com

TCD One of Spain's Top 5 Investment Opportunities in Biotechnology

Madrid, Spain 4th of October, 2010 -- Traslational Cancer Drugs Pharma, S.L. ("TCD" or the "Company") announced today that it has been chosen as one of Spain's top 5 investment opportunities in Biotechnology by a panel of experts as part of the Investors' Forum in BioSpain international Conference.

"This is a vote of confidence in the Company, its management and its business model" said TCD's CEO, Ran Vigdor, "We are grateful for the panel for choosing TCD and we are sure we will prove the panel right".

TCD is focused on the discovery, development and commercialization of innovative therapies that address unmet medical needs in the field of Oncology.

The Company's strategy is to identify, evaluate and in-license breakthrough discoveries and to rapidly advance them through the completion of Phase II of the Regulatory process. This is done by leveraging resources through collaborations and outsourcing via premier Contract Research Organizations, resulting in an efficient, flexible and effective process.

TCD is currently positioning itself as Spain's Partner of Choice for Oncology drug discovery and development opportunities.

In September 2010 TCD received the approval of the FDA for its Investigational New Drug (IND) application to begin a Phase I clinical study with its Choline Kinase Alpha inhibitor, TCD-717, for the treatment of solid tumors. The study will be conducted in two leading medical centers in the U.S and is scheduled to begin patients' recruitment in January 2011.

About the Trial

The trial is designed to primarily assess the safety and tolerability, pharmacokinetics and preliminary efficacy of TCD-717 given by intravenous infusion in patients with advanced solid tumors. Each patient will receive 2 weekly administrations of TCD-717 for a total of 6 cycles in the course of 28 days, unless disease progression or dose limiting toxicity occurs. Patients who do not have progressive disease after the last treatment will be offered to continue treatment. Patients will be enrolled in ascending dose cohorts of 3 patients and will be monitored for evidence of dose-limiting toxicity. Once the maximum tolerated dose is reached, additional patients will be enrolled to confirm this dose.

Choline Kinase Alpha (ChoKα)

Choline Kinase Alpha (ChoKα) is a key enzyme regulating the production of phosphatidylcholine, a critical structural component required for the formation of the cell's membrane and cell proliferation. Due to this role, ChoKα belongs to a very unique type of molecules that are essential for the carcinogenic process.
TCD has demonstrated that the up-regulation of ChoKα is a critical element for the acquisition of the tumor phenotype and that this enzyme participates in at least three of the major steps in the

generation of cancer: independent cell proliferation; evasion of apoptosis (cell death); and increased cell motility and metastasis.
ChoKα overexpression is an indicator of the more aggressive nature of the tumor. Thus, the use of ChoKα-inhibitors is expected to be effective in all tumor types including the more aggressive harder-to-treat cases. Lung cancer, breast cancer, colorectal cancer, ovarian cancer, prostate cancer and bladder cancer are just a few among the many cancer types characterized by ChoKα overexpression.

About TCD-717

TCD-717 is a first-in-class, small molecule that precisely inhibits ChoKα. By inhibiting ChoKα TCD-717 destroys the cancer cells with minimal effects on normal cells. The difference in response to ChoKα inhibition between cancer cells and normal cells derives from the addiction of tumor cells to phosphatidylcholine. While ChoKα inhibition causes a temporary and reversible arrest of proliferation in normal cells, the tumor cells attempt to overcome ChoKα inhibition by activation of an alternative mechanism for generating phosphatidylcholine. This alternative mechanism enables the cell, to some extent, to continue the phosphatidylcholine production process, however it also leads to the production of Ceramides, a lethal metabolite that promotes apoptosis (programmed cell death) and causes the specific destruction of the cancer cell. It is this different response to ChoKα inhibition between tumor cells and normal cells that makes TCD-717 a uniquely effective targeted treatment with an evident and overwhelming advantage over conventional, non-specific chemotherapy.

About the Company

Traslational Cancer Drugs Pharma S.L ("TCD" or the "Company") is a biotechnology corporation focused on the discovery, development and commercialization of innovative therapies that address unmet medical needs in the field of Oncology.
TCD's strategy is to identify, evaluate and in-license breakthrough discoveries and to rapidly advance them through the completion of Phase II of the Regulatory process. This is done by leveraging resources through collaborations and outsourcing via premier Contract Research Organizations, resulting in an efficient, flexible and effective process. Value to shareholders is generated by royalty-bearing licensing agreements.
The Company is positioning itself as Spain's Partner of Choice for Oncology drug discovery and development opportunities.